Form 4: Panbela Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Jennifer K. Simpson, President and CEO of Panbela Therapeutics, Inc., acquired stock options on October 1, 2024.
Summary
- On October 1, 2024, Jennifer K. Simpson, the President and CEO of Panbela Therapeutics, Inc. (PBLA), acquired 72,800 stock options.
- The exercise price of these options is $0.389.
- The options vest fully on October 1, 2025, contingent upon continuous service with the issuer.
- The options expire on October 1, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The acquisition of stock options by the CEO could align her interests more closely with those of the shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of earliest transaction: Jennifer K. Simpson acquired stock options. |
| 10/01/2025 | Date the options fully vest, subject to continuous service. |
| 10/01/2034 | Expiration date of the stock options. |
| 10/03/2024 | Date of the signature on the Form 4 filing. |
Keywords
stock options, Panbela Therapeutics, PBLA, Jennifer K. Simpson, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.